Norges Bank Blueprint Medicines Corp Transaction History

Norges Bank

$736 Billion
Q4 2024

A detailed history of Norges Bank transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Norges Bank holds 711,164 shares of BPMC stock, worth $67.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

711,164

Holding current value

$67.1 Million

% of portfolio

0.01%

48 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$82.48 - $101.39 $58.7 Million - $72.1 Million	711,164 New	711,164 $62 Million
Q2 2024 Aug 14, 2024	BUY	$85.18 - $108.78 $50.4 Million - $64.4 Million	592,126 New	592,126 $63.8 Million
Q4 2023 Feb 09, 2024	BUY	$43.96 - $92.84 $26.6 Million - $56.3 Million	605,951 New	605,951 $55.9 Million
Q3 2023 Nov 13, 2024	BUY	$46.9 - $66.0 $27.5 Million - $38.7 Million	585,996 New	585,996 $29.4 Million
Q3 2023 Nov 13, 2023	SELL	$46.9 - $66.0 $37.1 Million - $52.2 Million	-790,955 Closed	0 $0
Q2 2023 Aug 14, 2024	SELL	$42.2 - $66.37 $799,268 - $1.26 Million	-18,940 Reduced 3.2%	573,186 $36.2 Million
Q2 2023 Aug 14, 2023	SELL	$42.2 - $66.37 $25.9 Million - $40.8 Million	-614,901 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$37.97 - $50.0 $21.3 Million - $28 Million	560,792 New	560,792 $25.2 Million
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $26 Million - $42.2 Million	634,045 New	634,045 $27.8 Million
Q3 2022 Nov 13, 2023	BUY	$49.93 - $77.7 $39.5 Million - $61.5 Million	790,955 New	790,955 $52.1 Million
Q2 2022 Aug 14, 2023	BUY	$45.23 - $70.15 $27.8 Million - $43.1 Million	614,901 New	614,901 $31.1 Million
Q1 2022 May 12, 2023	BUY	$54.1 - $110.08 $9.98 Million - $20.3 Million	184,412 Added 29.09%	818,457 $52.3 Million
Q1 2022 May 09, 2022	SELL	$54.1 - $110.08 $43.6 Million - $88.7 Million	-806,188 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$94.25 - $115.99 $76 Million - $93.5 Million	806,188 New	806,188 $86.4 Million
Q3 2021 Nov 14, 2022	BUY	$80.98 - $109.47 $59.7 Million - $80.7 Million	737,157 New	737,157 $75.8 Million
Q3 2021 Nov 05, 2021	SELL	$80.98 - $109.47 $54.5 Million - $73.7 Million	-672,973 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$82.78 - $101.0 $55.7 Million - $68 Million	672,973 New	672,973 $59.2 Million
Q2 2021 Aug 10, 2021	SELL	$82.78 - $101.0 $58.8 Million - $71.7 Million	-709,908 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$90.71 - $108.28 $64.4 Million - $76.9 Million	709,908 New	709,908 $69 Million
Q1 2021 May 07, 2021	SELL	$90.71 - $108.28 $70.8 Million - $84.5 Million	-780,264 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$92.08 - $124.48 $71.8 Million - $97.1 Million	780,264 New	780,264 $87.5 Million
Q4 2020 Feb 10, 2021	SELL	$92.08 - $124.48 $90.2 Million - $122 Million	-979,314 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$66.45 - $92.7 $65.1 Million - $90.8 Million	979,314 New	979,314 $90.8 Million
Q3 2020 Nov 10, 2020	SELL	$66.45 - $92.7 $76.9 Million - $107 Million	-1,156,671 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$57.09 - $79.27 $66 Million - $91.7 Million	1,156,671 New	1,156,671 $90.2 Million
Q2 2020 Aug 07, 2020	SELL	$57.09 - $79.27 $89.6 Million - $124 Million	-1,569,812 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$48.11 - $82.22 $75.5 Million - $129 Million	1,569,812 New	1,569,812 $91.8 Million
Q1 2020 May 08, 2020	SELL	$48.11 - $82.22 $48 Million - $82 Million	-997,612 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$66.73 - $82.59 $66.6 Million - $82.4 Million	997,612 New	997,612 $79.9 Million
Q4 2019 Feb 12, 2020	SELL	$66.73 - $82.59 $48.9 Million - $60.5 Million	-732,212 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$72.9 - $101.41 $53.4 Million - $74.3 Million	732,212 New	732,212 $53.8 Million
Q3 2019 Nov 08, 2019	SELL	$72.9 - $101.41 $56.5 Million - $78.6 Million	-775,544 Closed	0 $0
Q2 2019 Aug 13, 2020	BUY	$73.54 - $97.8 $57 Million - $75.8 Million	775,544 New	775,544 $73.2 Million
Q2 2019 Aug 09, 2019	SELL	$73.54 - $97.8 $65.9 Million - $87.6 Million	-895,544 Closed	0 $0
Q1 2019 May 11, 2020	BUY	$48.7 - $86.6 $5.04 Million - $8.95 Million	103,393 Added 13.05%	895,544 $71.7 Million
Q4 2018 Mar 04, 2019	BUY	$45.57 - $74.26 $36.1 Million - $58.8 Million	792,151 New	792,151 $42.7 Million
Q4 2018 Feb 08, 2019	SELL	$45.57 - $74.26 $36.1 Million - $58.8 Million	-792,151 Closed	0 $0
Q3 2018 Nov 12, 2019	BUY	$58.91 - $78.32 $46.7 Million - $62 Million	792,151 New	792,151 $61.8 Million
Q3 2018 Nov 09, 2018	SELL	$58.91 - $78.32 $54.6 Million - $72.6 Million	-927,333 Closed	0 $0
Q2 2018 Aug 12, 2019	BUY	$60.96 - $101.18 $56.5 Million - $93.8 Million	927,333 New	927,333 $58.9 Million
Q2 2018 Jul 23, 2018	SELL	$60.96 - $101.18 $49.5 Million - $82.1 Million	-811,752 Closed	0 $0
Q1 2018 May 15, 2019	BUY	$73.28 - $102.95 $59.5 Million - $83.6 Million	811,752 New	811,752 $74.4 Million
Q1 2018 May 09, 2018	SELL	$73.28 - $102.95 $56.9 Million - $80 Million	-776,734 Closed	0 $0
Q4 2017 Mar 05, 2018	BUY	$62.91 - $88.32 $48.9 Million - $68.6 Million	776,734 New	776,734 $58.6 Million
Q4 2017 Feb 09, 2018	SELL	$62.91 - $88.32 $29.2 Million - $41 Million	-463,695 Closed	0 $0
Q3 2017 Nov 13, 2018	BUY	$42.37 - $69.67 $19.6 Million - $32.3 Million	463,695 New	463,695 $32.3 Million
Q3 2017 Nov 07, 2017	SELL	$42.37 - $69.67 $15.9 Million - $26.1 Million	-375,000 Closed	0 $0
Q2 2017 Jul 24, 2018	BUY	N/A	375,000	375,000 $19 Million

Others Institutions Holding BPMC

# of Institutions

380

Shares Held

65.9M

Call Options Held

1.6M

Put Options Held

1.41M

Vanguard Group Inc Valley Forge, PA

6.77M
Shares

$639 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.65M
Shares

$627 Million
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

5.68M
Shares

$536 Million
0.06% of portfolio
Wellington Management Group LLP Boston, MA

4.28M
Shares

$404 Million
0.07% of portfolio
State Street Corp Boston, MA

2.5M
Shares

$236 Million
0.01% of portfolio

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.63B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account